Polpharma Biologics

Polpharma Biologics, originally founded in 2012 and headquartered in the Netherlands, has undergone a significant transformation, splitting into two independent entities. The remaining Polpharma Biologics is now a pure-play biosimilars developer with a strategic base in Zug, Switzerland, focusing on building a targeted pipeline and forging global partnerships. The company has a commercial-stage asset, Tyruko®, and leverages an agile development model aimed at accelerating biosimilar approval and market access. Its former large-scale manufacturing and CDMO operations now reside with the separate company, Rezon Bio, based in Poland.

Integrated, agile biosimilar development process focused on analytical characterization, process development, and regulatory strategy, utilizing an asset-light, partnership-based model for manufacturing.

Polpharma Biologics competes with large, integrated generics/biosimilars companies (e.g., Sandoz, Biocon, Celltrion) and other focused biosimilar developers. Its differentiation lies in its agile, development-centric model and strategic focus on high-value, complex molecules. Success depends on speed-to-market and the strength of its partnership network against competitors with larger internal commercial and manufacturing scale.